CD274 and non-small cell lung carcinoma: Currently, the only biomarker driving treatment selection is PD-L1 expression, approved in Italy by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) for patients with NSCLC and melanoma.